糖尿病の新たな治療戦略

出版社： フジメディカル出版
著者：
発行日： 2014-06-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784862701510
電子書籍版： 2014-06-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,970 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

1,485 円(税込)

購入する

商品紹介

インクレチン関連薬をもってしてもなお、良好な血糖コントロールや低血糖・体重増加の解決に至っていないことが糖尿病治療の大きな課題となっています。糖尿病治療に貢献が期待される新規薬剤SGLT2阻害薬をいち早く取り上げ、その開発経緯、作用機序、種類と特徴（臨床薬理含む）、安全性、今後の課題と展望等を解説。

目次

  • 糖尿病の新たな治療戦略

    ―目次―

    1． 糖輸送体概論：GLUTs、SGLTsの分子構造の比較、
    　　　臓器局在と機能特性、糖輸送機構の違いについて

    2．SGLT2発見の歴史・経緯と腎尿細管糖再吸収機構

    3．腎性糖尿の遺伝子異常と糖尿病における
    　　腎尿細管糖輸送体発現異常

    4．SGLT2阻害薬の構造と機能

    5．SGLT2阻害薬の構造、生体内代謝、血中動態（PK,PDを含む）と
    　　臨床試験成績
    　1）イプラグリフロジン
    　2）ルセオグリフロジン
    　3）トホグリフロジン
    　4）ダパグリフロジン
    　5）カナグリフロジン
    　6）エンパグリフロジン

    6．SGLT2阻害薬の安全性

    7．SGLT2阻害薬の作用と適正使用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 糖輸送体概論 GLUTs, SGLTsの分子構造の比較, 臓器局在と機能特性, 糖輸送機構の違いについて

P.13 掲載の参考文献
1) Oka Y et al:C-terminal truncated glucose transporter is locked into an inward-facing form without transport activity. Nature 345(6275):550-553, 1990
PubMed
2) Mueckler M et al:Sequence and structure of a human glucose transporter. Science 229(4717):941-945, 1985
PubMed
3) Klip A:The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 34(3):481-487, 2009
PubMed
4) Hediger MA et al:Assignment of the human intestinal Na+ /glucose cotransporter gene(SGLT1) to the q11.2→qter region of chromosome 22. Genomics 4(3):297-300, 1989
 
5) You G et al:Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270(49):29365-29371, 1995
 

2. SGLT2の発見の歴史・経緯と腎尿細管糖再吸収機構

P.21 掲載の参考文献
1) Tahrani AA et al:Management of type 2 diabetes:new and future developments in treatment. Lancet 378(9786):182-197, 2011
PubMed
2) Wright EM et al:Biology of human sodium glucose transporters. Physiol Rev 91(2):733-794, 2011
PubMed
3) Bailey CJ:Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 32(2):63-71, 2011
PubMed
4) Rector FC Jr:Sodium, bicarbonate, and chloride absorption by the proximal tubule. Am J Physiol 244(5):F461-F471, 1983
PubMed
5) Barfuss DW, Schafer JA:Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 241(3):F322-F332, 1981
PubMed
6) Turner RJ, Moran A:Heterogeneity of sodium-dependent D-glucose transport sites along the proximal tubule:evidence from vesicle studies. Am J Physiol 242(4):F406-F414, 1982
PubMed
7) Hediger MA et al:Expression cloning and cDNA sequencing of the Na + /glucose co-transporter. Nature 330(6146):379-381, 1987
PubMed
8) Lee WS et al:The high affinity Na+ /glucose cotransporter:Re-evalution of function and tissue distribution of expression. J Biol Chem 269(16):12032-12039, 1994
 
9) You G et al:Molecular characterization of Na+ -coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem 270(49):29365-29371, 1995
 
10) Turk E et al:Glucose/galactose malabsorption caused by a defect in the Na+ /glucose cotransporter. Nature 350(6316):354-356, 1991
PubMed
11) Kanai Y et al:The human kidney low affinity Na+ /glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93(1):397-404, 1994
PubMed
12) van den Heuvel LP et al:Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter(SGLT2). Hum Genet 111(6):544-547, 2002
PubMed
13) Vallon V et al:SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22(1):104-112, 2011
PubMed
14) Gorboulev V et al:Na+-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61(1):187-196, 2012
 
15) 金井好克:栄養素トランスポーター:その研究の進展と今後の課題. 栄養・食品機能とトランスポーター(日本栄養・食糧学会監修,竹谷豊ほか編),建帛社,2011,pp1-18
 
16) 金井好克:総論. トランスポートソームの世界-膜輸送研究の源流から未来へ-(金井好克ほか編),京都廣川書店,2011,pp1-10
 
17) Abdul-Ghani MA et al:Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62(10):3324-3328, 2013
PubMed
18) Cefalu WT:Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 124(2):485-487, 2014
PubMed
19) Jurczak MJ et al:SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60(3):890-898, 2011
PubMed
20) Arakawa K et al:Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na +-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132(2):578-586, 2001
PubMed
21) Tsujihara K et al:Na+-glucose cotransporter(SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 42(26):5311-5324, 1999
 

3. 腎性糖尿の遺伝子異常と糖尿病における腎尿細管糖輸送体発現異常

P.27 掲載の参考文献
1) Arthur C Guyton et al:ガイトン生理学原著第11版,Arthur C Guyton et al,1,東京,エルゼビア・ジャパン,2010,pp341-346
 
2) Linda S Costanzo:コスタンゾ明解生理学,Linda S Costanzo,1,東京,エルゼビア・ジャパン,2011,pp277-279
 
3) van den Heuvel LP et al:Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter(SGLT2). Hum Genet 111(6):544-547, 2002
PubMed
4) Vestri S et al:Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182(2):105-112, 2001
PubMed
5) Marks J et al:Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 553:137-145, 2003
PubMed
6) Helliwell PA et al:Regulation of GLUT5, GLUT2 and intestinal brush-border fructose absorption by the extracellular signal-regulated kinase, p38 mitogen-activated kinase and phosphatidylinositol 3-kinase intracellular signalling pathways:implications for adaptation to diabetes. Biochem J 350:163-169, 2000
PubMed
7) Rahmoune H et al:Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54(12):3427-3434, 2005
PubMed

4. SGLT2阻害薬の構造と機能

P.31 掲載の参考文献
1) Ehrenkranz JR et al:Phlorizin:a review. Diabetes Metab Res Rev 21(1):31-38, 2005
PubMed
2) Rossetti L et al:Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80(4):1037-1044, 1987
PubMed
3) Rossetti L et al:Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79(5):1510-1515, 1987
PubMed
4) Bays H:Sodium Glucose Co-transporter Type 2(SGLT2) Inhibitors:Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther 4(2):195-220, 2013
PubMed
5) Crespy V et al:Bioavailability of phloretin and phloridzin in rats. J Nutr 131(12):3227-3230, 2001
PubMed
6) Oldendorf WH et al:Rapid, transient drop in brain glucose after intravenous phloretin or 3-0-methyl-D-glucose. Stroke 14(3):388-393, 1983
PubMed
7) Wright EM et al:Biology of human sodium glucose transporters. Physiol Rev 91(2):733-794, 2011
PubMed
8) Suzuki M et al:Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341(3):692-701, 2012
PubMed
9) Grempler R et al:Empagliflozin, a novel selective sodium glucose cotransporter-2(SGLT-2) inhibitor:characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14(1):83-90, 2012
PubMed
10) Washburn WN, Poucher SM:Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 22(4):463-486, 2013
PubMed
11) Kakinuma H et al:(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol(TS-071) is a potent, selective sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53(8):3247-3261, 2010
 

5. SGLT2阻害薬の構造, 生体内代謝, 血中動態と臨床試験成績

P.39 掲載の参考文献
1) Imamura M et al:Discovery of Ipragliflozin(ASP1941):a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2(SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 20(10):3263-3279, 2012
 
2) Washburn WN:Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 19(11):1485-1499, 2009
 
3) Tahara A et al:Pharmacological profile of ipragliflozin(ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385(4):423-436, 2012
PubMed
4) Veltkamp SA et al:Effect of Ipragliflozin(ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 31(12):839-851, 2011
PubMed
5) Kadokura T et al:Ipragliflozin(ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetology Int 2:172-182, 2011
 
6) Schwartz SL et al:Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin(ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13(12):1219-1227, 2011
PubMed
7) Smulders RA et al:No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab 14(10):937-943, 2012
PubMed
8) Kashiwagi A et al:Randomized, placebo-controlled, double-blind glycemic control trial of novel SGLT2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigaion(in press).
 
9) Fonseca VA et al:Active-and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 27(3):268-273, 2013
PubMed
10) Wilding JP et al:Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin:a dose-finding study. Diabetes Obes Metab 15(5):403-409, 2013
PubMed
11) Ferrannini E et al:Renal glucose handling:impact of chronic kidney disease and sodiumglucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 36(5):1260-1265, 2013
PubMed
P.48 掲載の参考文献
1) Kakinuma H et al:(1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol(TS-071) is a potent, selective sodium-dependent glucose cotransporter 2(SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 53(8):3247-3261, 2010
 
2) Chino Y et al:Pharmacokinetics and Prediction of Drug-Drug Interaction of TS-071 a Selective SGLT2 Inhibitor:the 26th JSSX Annual Meeting in Hiroshima, 16-18 November 2011, Poster Session 2-P2-28
 
3) Miyata A et al:Characterization of the Human Enzymes involved in the Metabolism of Luseogliflozin(TS-071), a Selective SGLT2 Inhibitor:the 28th JSSX Annual Meeting in Tokyo, 9-11 October 2013, Poster Session 2-G-P-17
 
4) Sasaki T et al:Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males:A Randomized, Single-Blind, Placebo-Controlled Trial. Adv Ther 31:345-361, 2014
 
5) Sasaki T et al:TS-071, a novel potent and highly selective renal sodium-glucose co-transporter 2(SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th European Association for the Study of Diabetes(EASD) Annual Meeting, September 12-16, 2011. Lisbon, Portugal, 2011
 
6) Sasaki T et al:Effect of gender and age on the pharmacokinetics of luseogliflozin(TS-071), a selective SGLT2 inhibitor [abstract]. Diabetes 61 supplement(s1):A275(1069-P), 2012
 
7) Haneda M et al:Luseogliflozin(TS-071), a selective SGLT2 inhibitor, improves glycemic control in Japanese type 2 diabetic subjects with renal impairment. Diabetologia 55(Supple 1):S303, 2012
 
8) Seino Y et al:Luseogliflozin, a SGLT2 inhibitor, improves glycaemic control and reduces body weight as monotherapy up to 52 weeks in Japanese patients with type 2 diabetes mellitus. Diabetologia 56(Supple 1):S82, 2013
 
9) Inagaki N et al:Luseogliflozin, a selective SGLT2 inhibitor, add on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients. Diabetologia 56(Supple 1):S384, 2013
 
10) Haneda M et al:Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycaemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus. Diabetologia 56(Supple 1):S384, 2013
 
11) 審議結果報告書ルセフィ錠(平成26年3月3日)Available at:http://www.info.pmda.go.jp/shinyaku/P201400033/400059000_22600AMX00540_A100_1.pdf
 
12) Johnsson KM et al:Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27(5):473-478, 2013
PubMed
13) Johnsson KM et al:Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27(5):479-484, 2013
PubMed
P.55 掲載の参考文献
1) 門脇孝ほか:新規血糖降下薬SGLT2阻害薬のこれからの糖尿病治療における位置づけ. Ther Res 34(11):1429-1440,2013
Medical*Online
2) 加来浩平ほか:新規SGLT2阻害薬Tofogliflozinの日本人2型糖尿病患者における有効性及び安全性の検証-第II/III相臨床試験結果-. 第56回日本糖尿病学会年次学術集会,熊本,5月16-18日,2013
 
3) Tanizawa Y et al:Efficacy and safety of tofogliflozin administered for 52 weeks as monotherapy or combined with other oral hypoglycemic agents in Japanese patients with type 2 diabetes. European Association for the Study of Diabetes(EASD) 49th Annual Meeting, Barcelona, September 23-27, 2013
 
4) Obata A et al:Tofogliflozin Improves Insulin Resistance as well as Glucose Tolerance by Ameliorating Fatty Liver and Obesity. American Diabetes Association(ADA) 73rd Annual Scientific Sessions, Chicago, IL, June 21-25, 2013
 
P.62 掲載の参考文献
1) Tirmenstein M et al:Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Int J Toxicol 32(5):336-350, 2013
PubMed
2) Kasichayanula S et al:Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet 53(1):17-27, 2014
PubMed
3) Zhang M et al:Dapagliflozin treatment for type 2 diabetes:a systematic review and metaanalysis of randomized controlled trials. Diabetes Metab Res Rev 30(3):204-221, 2013
 
4) Wilding JP et al:Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin:efficacy and safety over 2 years. Diabetes Obes Metab 16(2):124-136, 2014
PubMed
5) Lambers Heerspink HJ et al:Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15(9):853-862, 2013
PubMed
6) Bolinder J et al:Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97(3):1020-1031, 2012
PubMed
7) Bolinder J et al:Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16(2):159-169, 2014
PubMed
8) Kohan DE et al:Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962-971, 2014
 
9) Merovci A et al:Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509-514, 2014
PubMed
10) Kaku K et al:Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control:a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15(5):432-440, 2013
PubMed
11) Liu JJ et al:Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 61(9):2199-2204, 2012
PubMed
12) Abdul-Ghani MA et al:Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. Diabetes 62(10):3324-3328, 2013
PubMed
P.67 掲載の参考文献
1) Polidori D et al:Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion:results of a randomized, placebo-controlled study. Diabetes Care 36(8):2154-2161, 2013
PubMed
2) 酒井正樹ほか:腎糖排泄閾値を指標とした新規SGLT2阻害薬Canagliflozinの日本人2型糖尿病患者におけるPK/PDモデリング. 糖尿病55(suppl1):S-365,2012
 
3) DeFronzo RA et al:The role of the kidneys in glucose homeostasis:a new path towards normalizing glycaemia. Diabetes Obes Metab 14(1):5-14, 2012
PubMed
4) Inagaki N et al:Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes:a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 15(12):1136-1145, 2013
PubMed
5) Devineni D et al:Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53(6):601-610, 2013
PubMed
6) Cefalu WT et al:Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU):52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941-950, 2013
PubMed
7) Cefalu WT et al:Canagliflozin demonstrates durable glycemic improvements over 104 weeks versus glimepiride in subjects with type 2 diabetes mellitus on metformin. Diabetes 62(suppl1A):LB18, 2013
 
8) FDA Briefing Document NDA 204042 Invokana(canagliflozin) Tablets Endocrinologic and Metabolic Drugs Advisory Committee Meeting January 10, 2013 http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm336236.pdf
 
9) Stenlof K et al:Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372-382, 2013
PubMed
10) Yale JF et al:Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15(5):463-473, 2013
PubMed
11) Rosenstock J et al:Effects of Canagliflozin added on to basal insulin +/-other antihyperglycemic agents in type 2 diabetes. Diabetes 62(suppl1):A280, 2013
 
12) Fulcher G et al:Canagliflozin in subjects with type 2 diabetes mellitus inadequately controlled on sulfonylurea monotherapy:a CANVAS substudy. Diabetes 62(suppl1):A292, 2013
 
P.76 掲載の参考文献
1) Sarashina A et al:Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2(SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28(3):213-219, 2013
PubMed
2) Heise T et al:Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 15(7):613-621, 2013
PubMed
3) Macha S et al:Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes Metab. doi:10.1111/dom.12183, 2013
 
4) Macha S et al:Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2(SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab 16(3):215-222, 2014
PubMed
5) Ferrannini E et al:A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15(8):721-728, 2013
PubMed
6) Haring HU et al:EMPA-REG METSU Trial Investigators:Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes:a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36(11):3396-3404, 2013
PubMed
7) Kovacs CS et al:on behalf of the EMPA-REG PIO TM trial investigators:Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes:a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. doi:10.1111/dom.12188, 2013
 
8) Roden M et al:on behalf of the EMPA-REG MONO trial investigators:Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes:a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology 1(3):208-219, 2013
 

6. SGLT2阻害薬の安全性

P.83 掲載の参考文献
1) Kashiwagi A et al:Randomized, placebo-controlled, double-blind glycemic control trial of novel SGLT2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigaion(in press).
 
2) List JF et al:Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32(4):650-657, 2009
PubMed
3) Schernthaner G et al:Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week randomized trial. Diabetes Care 36(9):2508-2515, 2013
 
4) Ferrannini E et al:Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise:a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33(10):2217-2224, 2010
PubMed
5) Ljunggren O et al:Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 14(11):990-999, 2012
PubMed
6) Cefalu WT et al:Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin(CANTATA-SU):52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941-950, 2013
PubMed
7) Kohan DE et al:Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85(4):962-971, 2014
 
8) Lavalle-Gonzalez FJ et al:Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy:a randomised trial. Diabetologia 56(12):2582-2592, 2013
PubMed
9) Ferrannini E et al:A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15(8):721-728, 2013
PubMed
10) Nauck MA et al:Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin:a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34(9):2015-2022, 2011
 
11) Wilding JP et al:A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers:applicability of a novel insulin-independent treatment. Diabetes Care 32(9):1656-1662, 2009
PubMed
12) Vasilakou D et al:Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and meta-analysis. Ann Intern Med 159(4):262-274, 2013
PubMed

7. SGLT2阻害薬の作用と適正使用

P.91 掲載の参考文献
1) Ferrannini E et al:Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124(2):499-508, 2014 doi:10.1172/JCI72227
 
2) Merovci A et al:Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124(2):509-514, 2014 doi:10.1172/JCI70704
 
3) Cefalu WT:Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 124(2):485-487, 2014 doi:10.1172/JCI74297
 
4) ビグアナイド薬の適正使用委員会:ビグアナイド薬の適正使用に関するRecommendation. 日本糖尿病学会ホームページhttp://www.jds.or.jp/modules/important/index.php?page=article&storyid=20
 

書評

最近チェックした商品履歴

Loading...